Study finds RSV treatment Beyfortus prevents 5,800 hospitalisations in France
Roughly 5,800 hospitalisations from bronchiolitis were avoided in France thanks to the new preventive medicine nirsevimab, Public Health France said on Friday. The health agency cited two studies that showed that the antibody, which is marketed under the name Beyfortus, was effective at preventing severe cases of the illness in newborns caused by respiratory syncytial virus (RSV). The common respiratory virus causes cold-like symptoms but can be dangerous for newborns and older adults. It is the leading cause of paediatric hospitalisation in Europe. Cases of the virus surged following the COVI...